Michael Pishvaian, MD, PhD
Disclosures: Consulting Fee-AstraZeneca-Principal_Investigator Other_Role-Advisory board. Also, Study chair on one protocol|Consulting Fee-Perthera-Other_Role-Consultant; Stock|Consulting Fee-Merck and Company, Inc.-Other_Role-Advisory Board|Consulting Fee-Halozyme-Other_Role-Consultant|Consulting Fee-Foundation Medicine-Other_Role-Advisory Board|Grant to institution-Bavarian Nordic-Principal_Investigator-Funding to the institution for a trial - 01/29/2020

Mike Pishvaian is an Associate Professor in the Department of Oncology at Johns Hopkins University.  Dr. Pishvaian is an MD and has a PhD in Tumor Biology, having earned both degrees at Georgetown in 2001.  He remained at Georgetown after graduation, completing his medical residency in 2004, then his fellowship in Hematology/Oncology in 2007.  He served on the faculty at Georgetown until moving to MD Anderson in 2019.  At MD Anderson, he was the co-director for Clinical Research at the Zayed Center for Pancreatic Cancer Research.  He then moved to Johns Hopkins, and is the Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs at the National Capital Region Cancer Center.  On social media, Dr. Pishvaian is also the Founder of Tumor Board Tuesdays, a case-based weekly discussion on Twitter focusing on interesting biomarker-based therapies.


Dr. Pishvaian is a translational oncologist, focused on providing novel therapies for patients, particularly in the areas of pancreatic cancer and refractory colorectal cancer.  His work has been focused in the area of precision medicine, with a special focus on therapy targeted towards homologous recombination DNA repair deficient tumors, and Dr. Pishvaian is a Co-investigator on an NIH RO1 to study mechanisms of resistance to PARP inhibitor-based therapy, and a Co-PI of a U01 grant aimed at studying ex vivo patient derived models of cancer for patients with pancreatic cancer. Dr. Pishvaian also serves as the Alliance Co-Chair of the Pancreatic Cancer subcommittee, and the chair of TARGET-Panc, an ACCRU-supported effort to build biomarker-based clinical trials in Pancreatic Cancer.